logo BDSP

Base documentaire


  1. Newborn screening for sickle cell disease : 4 years of experience from California's nebworn screening program.

    Article - En anglais

    Purpose 

    In this article we describe the success of a unique newborn screening program for sickle cell disease and other hemoglobinopathies.

    We will present and discuss 4 years of experience from the California Newborn Hemoglobinopathy Screening Program.

    Methods 

    Several aspects that ensure the success of the program will be reviewed.

    These aspects include (a) the use of high-pressure liquid chromatography as the initial screening technique, (b) a confirmatory testing laboratory that incorporates DNA technology and innovative protein analysis using electrospray mass spectrometry, and (c) a complex follow-up strategy that employs regional nurses to track positive results and ensure timely enrollment of infants into treatment systems.

    Results 

    Of these 2 million infants screened, 492 were diagnosed with some form of sickle cell disease ; 290 (58.9%) were diagnosed with hemoglobin SS, 143 (29.0%) were diagnosed with hemoglobin SC, and 47 (9.5%) were diagnosed with Sbêta+thalassemia.

    Conclusion 

    The prevalence and ethnicity data presented here demonstrate the ineffectiveness of targeted screening and justify universal screening.

    Had targeted screening been performed in California during the past 4 years, 58 nonblack infants with sickle cell disease would have gone undiagnosed, and 6,921 nonblack infants with sickle cell trait would not have been identified.

    Mots-clés Pascal : Anémie hématie falciforme, Dépistage, Prévalence, Facteur risque, Distribution, Epidémiologie, Nouveau né, Homme, Californie, Etats Unis, Amérique du Nord, Amérique, Hémopathie, Anémie hémolytique, Hémoglobinopathie, Maladie héréditaire

    Mots-clés Pascal anglais : Sickle cell anemia, Medical screening, Prevalence, Risk factor, Distribution, Epidemiology, Newborn, Human, California, United States, North America, America, Hemopathy, Hemolytic anemia, Hemoglobinopathy, Genetic disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0130112

    Code Inist : 002B19A01. Création : 199608.